These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 12593383)

  • 1. Protection from nuke side effects.
    TreatmentUpdate; 2002 Dec; 14(9):3-4. PubMed ID: 12593383
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing nuke toxicity.
    TreatmentUpdate; 2002 Mar; 14(3):3-4. PubMed ID: 12033187
    [No Abstract]   [Full Text] [Related]  

  • 3. NRTI-related mitochondrial toxicity in an HIV-infected woman.
    Jenny-Avital ER
    AIDS Clin Care; 2003 Oct; 15(10):87-9. PubMed ID: 14666921
    [No Abstract]   [Full Text] [Related]  

  • 4. Researcher presents vexing information on rilpivirine.
    Dalton P
    Proj Inf Perspect; 2008 Sep; (46):10-2. PubMed ID: 19048650
    [No Abstract]   [Full Text] [Related]  

  • 5. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
    Sax PE
    AIDS Clin Care; 2005 Jan; 17(1):6-7. PubMed ID: 15717372
    [No Abstract]   [Full Text] [Related]  

  • 6. [Favorable new data for nevirapine. Antiretroviral effect confirmed--and also lipid profile].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():58-60. PubMed ID: 15373051
    [No Abstract]   [Full Text] [Related]  

  • 7. Complications & side effects. Nukes and fat wasting.
    TreatmentUpdate; 2004; 16(7):3-4. PubMed ID: 17225282
    [No Abstract]   [Full Text] [Related]  

  • 8. Tenofovir--long term results from first-line therapy.
    TreatmentUpdate; 2003; 15(2):4-6. PubMed ID: 12693361
    [No Abstract]   [Full Text] [Related]  

  • 9. French investigators warn of LPV/TDF/ddI interaction.
    Carter M
    IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
    [No Abstract]   [Full Text] [Related]  

  • 10. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 11. Nevirapine precautions published.
    AIDS Treat News; 2004 Feb; (398):5. PubMed ID: 15119290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. To nuke, or not to nuke?
    Proj Inf Perspect; 2007 Apr; (43):1-3. PubMed ID: 17684823
    [No Abstract]   [Full Text] [Related]  

  • 13. Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study.
    Gewurz BE; Jacobs M; Proper JA; Dahl TA; Fujiwara T; Dezube BJ
    J Infect Dis; 2004 Dec; 190(11):1957-61. PubMed ID: 15529260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HIV agents. Five-year results from an NNRTI-based regimen.
    TreatmentUpdate; 2005; 17(1):6. PubMed ID: 17225317
    [No Abstract]   [Full Text] [Related]  

  • 15. Vaccines for HIV--Remune returns.
    TreatmentUpdate; 2004 Oct; 16(6):3. PubMed ID: 17219678
    [No Abstract]   [Full Text] [Related]  

  • 16. Detectable viral loads and slow development of resistance.
    Gadd C
    IAPAC Mon; 2005 Oct; 11(10):295-6. PubMed ID: 16673496
    [No Abstract]   [Full Text] [Related]  

  • 17. [HIV-infection: modern antiretroviral therapy].
    Rockstroh JK; Spengler U
    Dtsch Med Wochenschr; 2004 Sep; 129(37):1921-4. PubMed ID: 15372371
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-HIV agents. Continuing or stopping 3TC.
    TreatmentUpdate; 2005; 17(5):7-8. PubMed ID: 17219658
    [No Abstract]   [Full Text] [Related]  

  • 19. Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008).
    Pujari S; Patel A; Joshi SR; Gangakhedkar R; Kumarasamy N; Gupta SB;
    J Assoc Physicians India; 2008 May; 56():339-48, 353-71. PubMed ID: 18700643
    [No Abstract]   [Full Text] [Related]  

  • 20. Mutation and control of the human immunodeficiency virus.
    Stengel RF
    Math Biosci; 2008 Jun; 213(2):93-102. PubMed ID: 18439629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.